Stagljar Lab is a biochemistry and molecular genetics research group at the University of Toronto, Canada, and located in the Donnelly Centre, a cutting-edge scientific institute in the heart of Toronto's discovery district.

We currently direct major artificial intelligence projects focused on improving the diagnosis and therapeutic targets of serious diseases including cancer and cystic fibrosis.

We currently direct major artificial intelligence projects focused on improving the diagnosis and therapeutic targets of serious diseases including cancer and cystic fibrosis.

Perturba Therapeutics Launches

Cyclica and Stagljar Lab have joined forces to launch Perturba Therapeutics, a neo-biotech project. Perturba will integrate Cyclica’s comprehensive AI-augmented proteome-wide drug design technology with the Stagljar Lab's first-in-class live cell-based assays to expand on the currently small subset of biologically important drug targets that are being explored within the pharma industry. Learn more.

Stagljar Lab is one of the world leaders in the field of proteomics and chemical genomics

Major proteomics and chemical genomics projects currently under development in the lab:

Map how protein interaction produces either healthy or diseased cells

Identify novel therapeutic targets

Use AI to screen for new drugs for cancer and cystic fibrosis

EMI1: New EGFR-triple mutant inhibitor

Stagljar Lab is working on the further development of a novel EGFR-triple mutant inhibitor, named EMI1. EMI1 inhibits the signaling of EGFR-triple mutant lung cancer cells in a completely new way, leveraging molecular machineries to degrade mutated EGFR protein on the surface of tumor cells.

We hypothesize that EMI1’s complex mechanism of action will make it more difficult for lung tumors to develop resistance to it.

EMI1 stops the signaling of EGFR-triple mutant lung cancer cells in a  new way

140+

Publications

$38M+

research grants

8

Patents

2

Biotech Spinouts

Fighting Covid-19 with SATiN

In only seven months, we developed an innovative and cost-effective COVID-19 serological test named SATiN (for Serological Assay based on split Tripart Nanoluciferase).

A description of this technology was published in Nature Communications and was featured in major TV segments and news media publications in Canada and abroad. Learn more.

Stagljar Lab has made major contributions to the fight against COVID-19 by developing fast cheap tests and vaccine efficacy studies

SATiN Tests for Covid Variants

In collaboration with Shawn Owen’s lab at the University of Utah, the Stagljar lab has also recently further modified this split-luciferase assay so that it can be used to detect the presence and potency of neutralizing antibodies against SARS-CoV-2, including the wild-type and all major variants of concern.

This recent work on COVID-19 is an excellent example of how a productive and efficient lab is able to respond quickly to current needs during this pandemic with innovative technology development.

Stagljar Lab Team

It takes a dedicated, hard working team to do top of the line research as well as a slew of international collaborators. Learn more about the people behind the science.

Stagljar Lab group 2021
Stagljar Lab group photo summer 2021
Stagljar Lab group photo summer 2021
Stagljar Lab group photo summer 2021